VSTM just “trugs” along in the preliminary stages of clinical development with twists and turns but nothing that upsets the apple cart – but great cash position! VSTM closed at $9.68 on 5/9 DOWN from $9.74 on 5/8 on minimal 2700 shares. The combination trial of VS-6063 plus paclitaxel for ovarian cancer is open and enrolling patients at all sites. In addition, VSTM has met with the regulatory agencies in the US and UK and are on track to initiate midyear the potentially pivotal trial of VS-6063 in mesothelioma. 2013 milestones include the following: Complete the dose finding portion of the P1/1b trial of VS-6063 plus paclitaxel in ovarian cancer; Initiate P1 clinical development of VS-4718 H1 2013 and Initiate P1 clinical development of VS-5584 H2 2013. A …HOLD as I don’t see any great expectation in a Q or 2!
Hw, what is surprises me that for such early (and not entirely clear how potent) stage of drug development, the market value is close to 200M, while a lot of other companies on the same stage are valued 1/4-1/3 of it.
What is in your view "the secret" here?
(I do not have now any position, (studying what is going on with p53 ran into company name) but consider estabishing)